Kevin Mahoney: Announced this morning, Carl is a winner of the 2024 Breakthrough Prize in Life Sciences for the development of chimeric antigen receptor (CAR) T cell immunotherapy.

Quoting Kevin Mahoney, Chief Executive Officer at the University of Pennsylvania Health System, on LinkedIn:

”Dr. Carl June came to Penn Medicine, University of Pennsylvania Health System about three years after I joined the institution. His recruitment in 1999 was part of the organization’s push to build a global hub for cell and gene therapy. As Carl’s colleague and friend, I was granted a front-row seat to history being made. Over decades, his research changed how the world understands immunotherapy and led to the first FDA approval for CAR T cell therapy in 2017.

Today, we celebrate another defining moment in Carl’s impressive career. Announced this morning, Carl is a winner of the 2024 Breakthrough Prize in Life Sciences for the development of chimeric antigen receptor (CAR) T cell immunotherapy, a revolutionary treatment approach in which a patient’s T cells are modified to target and kill cancer cells.

The Breakthrough Prizes are the world’s largest science awards, with $3 million awarded for each of the five main prize categories. Carl is the sixth Breakthrough Prize laureate from Penn Medicine. He joins Drew Weissman, M.D., Ph.D.; Katalin Karikó, Ph.D.; Virginia M.Y. Lee, Ph.D.; Charles Kane, Ph.D.; and Eugene Mele, Ph.D., all from Penn Medicine, in receiving the distinction from the Breakthrough Prize Foundation.

The more than 270-year timeline that defines Penn Medicine is dotted with accolades, scientific discovery, and patient care advances. With today’s recognition, we add another milestone and honor Carl’s vast contributions to immunotherapy and cancer treatment.”

For the article click here.
Source: Kevin Mahoney/LinkedIn